Geron (GERN) Competitors $3.99 +0.20 (+5.28%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends GERN vs. KDNY, ORGO, FHTX, ZIOP, RGEN, MDGL, HALO, IONS, ALKS, and FOLDShould you be buying Geron stock or one of its competitors? The main competitors of Geron include Chinook Therapeutics (KDNY), Organogenesis (ORGO), Foghorn Therapeutics (FHTX), ZIOPHARM Oncology (ZIOP), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), and Amicus Therapeutics (FOLD). These companies are all part of the "medical" sector. Geron vs. Chinook Therapeutics Organogenesis Foghorn Therapeutics ZIOPHARM Oncology Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Alkermes Amicus Therapeutics Geron (NASDAQ:GERN) and Chinook Therapeutics (NASDAQ:KDNY) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends. Do analysts rate GERN or KDNY? Geron currently has a consensus price target of $7.05, suggesting a potential upside of 76.69%. Given Geron's stronger consensus rating and higher possible upside, equities research analysts plainly believe Geron is more favorable than Chinook Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00Chinook Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer GERN or KDNY? In the previous week, Geron had 3 more articles in the media than Chinook Therapeutics. MarketBeat recorded 3 mentions for Geron and 0 mentions for Chinook Therapeutics. Chinook Therapeutics' average media sentiment score of 0.67 beat Geron's score of 0.56 indicating that Chinook Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Geron Positive Chinook Therapeutics Positive Do insiders & institutionals believe in GERN or KDNY? 73.7% of Geron shares are owned by institutional investors. Comparatively, 95.2% of Chinook Therapeutics shares are owned by institutional investors. 3.1% of Geron shares are owned by insiders. Comparatively, 16.8% of Chinook Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, GERN or KDNY? Geron has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Chinook Therapeutics has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Does the MarketBeat Community prefer GERN or KDNY? Geron received 463 more outperform votes than Chinook Therapeutics when rated by MarketBeat users. Likewise, 69.90% of users gave Geron an outperform vote while only 50.00% of users gave Chinook Therapeutics an outperform vote. CompanyUnderperformOutperformGeronOutperform Votes49069.90% Underperform Votes21130.10% Chinook TherapeuticsOutperform Votes2750.00% Underperform Votes2750.00% Which has preferable valuation and earnings, GERN or KDNY? Geron has higher revenue and earnings than Chinook Therapeutics. Geron is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$29.48M81.82-$184.13M-$0.32-12.47Chinook Therapeutics$6.13M473.15-$187.87M-$3.52-11.47 Is GERN or KDNY more profitable? Geron has a net margin of -682.48% compared to Chinook Therapeutics' net margin of -4,199.93%. Chinook Therapeutics' return on equity of -58.28% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Geron-682.48% -67.53% -45.46% Chinook Therapeutics -4,199.93%-58.28%-44.72% SummaryGeron beats Chinook Therapeutics on 12 of the 19 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.29B$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-12.4710.57134.3717.77Price / Sales81.82243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book8.675.474.674.68Net Income-$184.13M$153.61M$119.07M$226.08M7 Day Performance7.55%-2.00%-1.83%-1.04%1 Month Performance1.01%-7.47%-3.62%1.04%1 Year Performance107.81%31.80%31.63%26.28% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron3.492 of 5 stars$3.99+5.3%$7.05+76.7%+98.5%$2.29B$29.48M-12.47141KDNYChinook TherapeuticsN/A$40.39flatN/AN/A$2.90B$6.13M-11.47214ORGOOrganogenesis4.0957 of 5 stars$3.97-2.7%$5.33+34.3%+51.5%$540.91M$433.14M0.00950Analyst RevisionFHTXFoghorn Therapeutics2.6424 of 5 stars$7.86+0.8%$16.00+103.6%+91.2%$436.96M$25.52M-4.09120ZIOPZIOPHARM OncologyN/AN/AN/AN/A$187.12MN/A-2.01105Analyst ForecastRGENRepligen4.6338 of 5 stars$138.90+8.1%$190.25+37.0%-10.8%$7.20B$638.76M0.001,783Positive NewsMDGLMadrigal Pharmaceuticals3.796 of 5 stars$317.09+0.9%$347.33+9.5%+66.8%$6.85BN/A-12.6490Analyst ForecastHALOHalozyme Therapeutics4.9806 of 5 stars$45.76+2.1%$61.11+33.5%+14.4%$5.82B$829.25M15.15390Analyst ForecastIONSIonis Pharmaceuticals4.2197 of 5 stars$35.40+4.9%$60.65+71.3%-28.7%$5.33B$803.07M-14.51800ALKSAlkermes4.7788 of 5 stars$27.91+1.6%$35.42+26.9%+15.4%$4.45B$1.51B14.312,100Positive NewsFOLDAmicus Therapeutics4.6577 of 5 stars$9.59+0.7%$17.63+83.8%-13.1%$2.84B$493.67M-28.21480 Related Companies and Tools Related Companies KDNY Competitors ORGO Competitors FHTX Competitors ZIOP Competitors RGEN Competitors MDGL Competitors HALO Competitors IONS Competitors ALKS Competitors FOLD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GERN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
